Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common β subunit

Abstract

Several constitutively active mutant forms of the common β subunit of the human IL-3, IL-5 and GM-CSF receptors (hβc), which enable it to signal in the absence of ligand, have recently been described. Two of these, V449E and I374N, are amino acid substitutions in the transmembrane and extracellular regions of hβc, respectively. A third, FIΔ, contains a 37 amino acid duplication in the extracellular domain. We have shown previously that when expressed in primary murine haemopoietic cells, the extracellular mutants confer factor-independence on cells of the neutrophil and monocyte lineages only, whereas V449E does so on all cell types of the myeloid and erythroid compartments. To study the in vivo effects and leukaemic potential of these mutants, we have expressed all three in mice by bone marrow reconstitution using retrovirally infected donor cells. Expression of the extracellular mutants leads to an early onset, chronic myeloproliferative disorder marked by elevations in the neutrophil, monocyte, erythrocyte and platelet lineages. In contrast, expression of V449E leads to an acute leukaemia-like syndrome of anaemia, thrombocytopaenia and blast cell expansion. These data support the possibility that activating mutations in hβc are involved in haemopoietic disorders in man.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Barry SC, Bagley CJ, Phillips J, Dottore M, Cambareri B, Moretti P, D'Andrea R, Goodall GJ, Shannon MF, Vadas MA and Lopez AF. . 1994 J. Biol. Chem. 269: 8488–8492.

  • Barry SC, Moretti PAB, Korpeleinen E, D'Andrea R, Lopez AF, Vadas MA and Goodall GJ. . 1997 Blood 89: 842–852.

  • Chang JM, Metcalf D, Gonda TJ and Johnson GR. . 1989a J. Clin. Invest. 84: 1488–1496.

  • Chang JM, Metcalf D, Lang RA, Gonda TJ and Johnson GR. . 1989b Blood 73: 1487–1497.

  • D'Andrea R, Rayner J, Moretti P, Lopez A, Goodall GJ, Gonda TJ and Vadas MA. . 1994 Blood 83: 2802–2808.

  • D'Andrea RJ, Harrison-Findik D, Butcher CM, Finnie J, Blumbergs P, Bartley P, McCormack MP, Jones K, Rowland R, Gonda TJ and Vadas MA. . 1998 J. Clin. Invest. 102: 1951–1960.

  • de Jong MO, Westerman Y, Wagemaker G and Wognum AW. . 1997 Stem Cells 15: 275–285.

  • Doi H, Inaba M, Yammamoto Y, Taketani S, Mori SI, Sugihara A, Ogata H, Toki J, Hisha H, Inaba K, Sogo S, Adachi M, Matsuda T, Good RA and Ikehara S. . 1997 Proc. Natl. Acad. Sci. USA 94: 2513–2517.

  • Freedman MH, Grunberger T, Correa P, Axelrad AA, Dube ID and Cohen A. . 1993 Blood 81: 3068–3075.

  • Gonda TJ and D'Andrea RJ. . 1997 Blood 89: 355–369.

  • Gualtieri RJ, Emanuel PD, Zuckerman KS, Martin G, Clark SC, Shadduck RK, Dracker RA, Ackabutu J, Nitschke R, Hetherington ML, Dickerman JD, Hakami N and Castleberry RP. . 1989 Blood 74: 2360.

  • Ihle JN. . 1995 Adv. Immunol. 60: 1–35.

  • Jenkins BJ, D'Andrea RJ and Gonda TJ. . 1995 EMBO J. 14: 4276–4287.

  • Jenkins BJ, Blake TJ and Gonda TJ. . 1998 Blood 92: 1989–2002.

  • Jenkins BJ, Le F and Gonda TJ. . 1999 J. Biol. Chem. 274: 8669–8677.

  • Johnson GR, Gonda TJ, Metcalf D, Hariharan IK and Cory S. . 1989 EMBO J. 8: 441–448.

  • Kaufman DC, Baer MR, Gao XZ, Wang ZQ and Preisler HD. . 1988 Blood 72: 1329–1332.

  • Lang RA, Metcalf D, Cuthbertson RA, Lyons I, Stanley E, Kelso A, Kannourakis G, Williamson DJ, Klintworth GK, Gonda TJ and Dunn AR. . 1987 Cell 51: 675–686.

  • Mann R, Mulligan RC and Baltimore D. . (1983) Cell 33: 153–159.

  • McCormack MP and Gonda TJ. . 1997 Blood 90: 1471–1481.

  • Metcalf D. . 1984 Clonal culture of hemopoietic cells: techniques and applications. Elsevier, Amsterdam.

    Google Scholar 

  • Metcalf D, Begley CG, Johnson GR, Nicola NA, Vadas MA, Lopez AF, Williamson DJ, Wong GG, Clark SC and Wang EA. . 1986a Blood 67: 37–45.

  • Metcalf D, Burgess GR, Johnson GR, Nicola NA, Nice EC, DeLamarter J, Thatcher GR and Mermod J. . 1986b J. Cell. Physiol. 128: 421–431.

  • Metcalf D, Begley CG, Williamson DJ, Nice EC, De Lamarter J, Mermod JJ, Thatcher D and Schmidt A. . 1987 Exp. Hematol. 15: 1–10.

  • Metcalf D and Nicola NA. . 1995 The Hemopoietic Colony-Stimulating Factors; From Biology to Clinical Applications. Cambridge University Press, Cambridge.

    Book  Google Scholar 

  • Miyajima A, Mui AL, Ogorochi T and Sakamaki K. . 1993 Blood 82: 1960–1974.

  • Nishijima I, Nakahata T, Watanabe S, Tsuji K, Tanaka I, Hirabayashi Y, Inoue T and Arai K. . 1997 Blood 90: 1031–1038.

  • Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y and Suda T. . 1992 Blood 80: 3044–3050.

  • Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G and Ihle JN. . 1998 Cell 93: 385–395.

  • Polotskaya A, Zhao Y, Lilly ML and Kraft AS. . 1993 Cell Growth Differ. 4: 523–531.

  • Sakamaki K, Miyajima I, Kitamura T and Miyajima A. . 1992 EMBO J. 11: 3541–3549.

  • Takaki S, Kanazawa H, Shiiba M and Takatsu K. . 1994 Mol. Cell. Biol. 14: 7404–7413.

  • Uchida N and Weissman IL. . 1992 J. Exp. Med. 175: 175–184.

  • Young DC, Wagner K and Griffin JD. . 1987 J. Clin. Invest. 79: 100–106.

  • Young DC and Griffin JD. . 1986 Blood 68: 1178–1181.

Download references

Acknowledgements

We wish to thank Drs Petranel Ferrao, Leonie Ashman and Hayley Ramshaw for assistance in setting up the bone marrow reconstitution system, and Dr Fei Le, Dr Anna Brown and Ms Jodi Lutwyche for assistance with RT – PCR. We also thank Dr Greg Goodall for critical reading of the manuscript. This work was supported in part by grants (to TJ Gonda) from the National Health and Medical Research Council of Australia (NH&MRC). MPM was a recipient of an Australian Postgraduate Award from the University of Adelaide. TJ Gonda is a Senior Research Fellow of the NH&MRC.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McCormack, M., Gonda, T. Myeloproliferative disorder and leukaemia in mice induced by different classes of constitutive mutants of the human IL-3/IL-5/GM-CSF receptor common β subunit. Oncogene 18, 7190–7199 (1999). https://doi.org/10.1038/sj.onc.1203226

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203226

Keywords

This article is cited by

Search

Quick links